New results show promise in treatment of SOD1-ALS

lesturnerClinical Trials, Foundation Blog, Home Page, Research News

New results from the Phase 3 clinical trial of tofersen, a drug in development by Biogen, have shown promise in treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). According to the 12-month data, earlier initiation of treatment with …

Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS

lesturnerClinical Trials, Foundation Blog, Home Page, Research News

We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020)  in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …

Data from Amylyx’s CENTAUR trial shows promise in slowing ALS progression

lesturnerClinical Trials, Foundation Blog, Home Page, Research News

We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline …

Introducing the First-Ever ALS Platform Trial

lesturnerClinical Trials, Home Page, Research News

The Sean M. Healey & AMG Center at Massachusetts General Hospital is launching the first-ever ALS platform trial aimed at advancing the development of ALS treatments. Our Lois Insolia ALS Clinic at the Les Turner ALS Center at Northwestern Medicine …